Drugs Containing Excipient (Inactive Ingredient) ETHYLENE-VINYL ACETATE COPOLYMER

Branded drugs containing ETHYLENE-VINYL ACETATE COPOLYMER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	NUVARING	etonogestrel and ethinyl estradiol	0052-0273	ETHYLENE-VINYL ACETATE COPOLYMER
Organon USA Inc	NEXPLANON	etonogestrel	0052-4330	ETHYLENE-VINYL ACETATE COPOLYMER	2029-01-16
Haleon US Holdings LLC	NICODERM	nicotine	0135-0194	ETHYLENE-VINYL ACETATE COPOLYMER
A-S Medication Solutions	NUVARING	etonogestrel and ethinyl estradiol	50090-1008	ETHYLENE-VINYL ACETATE COPOLYMER
A-S Medication Solutions	NUVARING	etonogestrel and ethinyl estradiol	50090-5611	ETHYLENE-VINYL ACETATE COPOLYMER

Generic drugs containing ETHYLENE-VINYL ACETATE COPOLYMER excipient

Company	Ingredient	NDC	Excipient
Organon USA Inc	etonogestrel and ethinyl estradiol	0052-0273	ETHYLENE-VINYL ACETATE COPOLYMER
Organon USA Inc	etonogestrel	0052-4330	ETHYLENE-VINYL ACETATE COPOLYMER
Teva Pharmaceuticals USA Inc	etonogestrel and ethinyl estradiol	0093-7679	ETHYLENE-VINYL ACETATE COPOLYMER
Haleon US Holdings LLC	nicotine	0135-0194	ETHYLENE-VINYL ACETATE COPOLYMER
SpecGx LLC	fentanyl transdermal	0406-9025	ETHYLENE-VINYL ACETATE COPOLYMER

Ethylene-Vinyl Acetate Copolymer Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 24, 2026

Ethylene-vinyl acetate copolymer is a niche pharmaceutical excipient used primarily in controlled-release systems, drug-eluting implants, medical devices, transdermal systems, and specialty solid dosage applications. Its pharmaceutical market is small relative to the global EVA polymer market, which is driven by packaging, photovoltaic encapsulants, footwear, wire and cable, and adhesives.

The commercial outlook is positive but highly specialized. Pharmaceutical-grade EVA benefits from long product qualification cycles, limited supplier substitution, and strong technical barriers. Revenue growth is constrained by the small number of approved drug-delivery products and by competition from biodegradable polymers, silicones, polyurethane systems, acrylic polymers, and other controlled-release materials.

What is ethylene-vinyl acetate copolymer used for in pharmaceuticals?

Ethylene-vinyl acetate, commonly abbreviated EVA or EVAc, is a copolymer of ethylene and vinyl acetate. Vinyl acetate content, molecular weight, crystallinity, melt behavior, and pellet or resin form determine permeability, flexibility, processability, and drug-release performance.

Pharmaceutical uses include:

Application	Function of EVA	Commercial relevance
Drug-eluting implants	Semipermeable or rate-controlling polymer matrix	High technical value, low volume
Long-acting delivery systems	Controls diffusion of active ingredients	Used where sustained release is required
Transdermal systems	Provides a flexible polymer matrix or membrane	Competes with polyurethane and silicone
Oral controlled-release dosage forms	Matrix or coating polymer	More limited than conventional hydrophilic matrices
Ophthalmic inserts	Controls release from implantable or insertable systems	Specialty application
Medical devices	Polymer carrier for antimicrobial or pharmaceutical agents	Often regulated as part of the finished device
Process and formulation aid	Modifies mechanical or release properties	Requires product-specific qualification

EVA is generally hydrophobic and does not dissolve rapidly in gastrointestinal fluids. Drug release typically occurs through diffusion, pores, channels, or erosion of a composite system. The polymer’s low water uptake can support long release periods but can also limit formulation flexibility.

A critical nomenclature issue affects market analysis. Ethylene-vinyl acetate copolymer is different from vinylpyrrolidone-vinyl acetate copolymer, often marketed as PVP/VA or copovidone. PVP/VA is a water-soluble pharmaceutical binder and film former. It is not the same material as EVA.

How large is the pharmaceutical ethylene-vinyl acetate market?

No major public market database separately reports pharmaceutical-grade EVA revenue. Published EVA market estimates generally combine all applications and grades, including photovoltaic encapsulation, packaging, footwear, adhesives, and industrial products. Those estimates cannot be used as a direct measure of pharmaceutical demand.

The pharmaceutical segment is best characterized as a high-value, low-volume niche within the broader EVA market.

Market attribute	Assessment
Global polymer volume	Large and diversified
Pharmaceutical volume	Small relative to industrial demand
Unit economics	Higher for qualified medical and pharmaceutical grades
Number of suppliers	Limited compared with commodity packaging grades
Customer concentration	High, because demand is linked to approved products
Switching cost	High after formulation and regulatory qualification
Growth driver	Long-acting delivery, implants, and specialty devices
Main constraint	Limited number of commercial drug products using EVA

A pharmaceutical EVA supplier can obtain better margins than a commodity polymer producer if it sells a qualified grade with controlled molecular weight, documented extractables and leachables data, lot traceability, and regulatory support. The premium is based on qualification and documentation rather than on polymer chemistry alone.

What drives demand for pharmaceutical-grade EVA?

Long-acting drug delivery

The principal demand driver is controlled drug release. EVA can provide predictable diffusion barriers for low- and medium-molecular-weight active ingredients. Its hydrophobicity makes it useful where formulation developers need release periods extending from weeks to years.

Demand depends on the number of approved products using the polymer. A new implant or depot formulation can generate recurring resin demand, but the volume per product is usually modest. This creates an unusual commercial profile: high technical switching costs but limited absolute material consumption.

Drug-eluting medical devices

EVA can be incorporated into devices that release an active ingredient over a defined period. These products may fall under drug, device, or combination-product regulatory pathways depending on the product design and jurisdiction.

Device applications can have more stable demand than early-stage pharmaceutical development because polymer specifications become embedded in manufacturing procedures and device master records. The market is still exposed to product discontinuation, reimbursement pressure, and changes in device design.

Specialty oral dosage forms

EVA can be used in hydrophobic matrices and coatings, but it competes with ethylcellulose, polymethacrylates, hypromellose systems, lipid matrices, and insoluble acrylate polymers. Oral applications are more sensitive to processability, content uniformity, residual solvents, and dissolution variability.

How does the broader EVA market affect pharmaceutical excipient pricing?

The financial trajectory of EVA is linked to ethylene and vinyl acetate monomer costs, plant utilization, energy prices, logistics, and demand in nonpharmaceutical sectors.

The largest commercial influences are usually outside pharmaceuticals:

1. Photovoltaic encapsulant demand can tighten EVA supply and raise resin prices.
2. Packaging demand can affect commodity-grade plant utilization.
3. Ethylene and vinyl acetate monomer costs determine the base polymer cost.
4. Capacity additions can reduce pricing pressure when demand growth slows.
5. Energy and freight costs affect regional supply economics.

This creates a mixed exposure for pharmaceutical customers. Strong solar or packaging demand can improve supplier economics and support investment in production capacity. It can also divert capacity toward higher-volume applications, increase lead times, and raise prices for specialty grades.

Financial factor	Effect on pharmaceutical EVA
Ethylene price	Raises or lowers polymer cost base
Vinyl acetate monomer price	Directly affects copolymer economics
Photovoltaic demand	Can tighten supply and increase utilization
Pharmaceutical qualification	Supports price premium and retention
Low pharmaceutical volumes	Limits economies of scale
Dedicated quality systems	Increase operating cost
Long-term supply agreements	Improve visibility but may limit spot pricing

Which companies supply or manufacture EVA relevant to pharmaceuticals?

The EVA supply base includes large petrochemical producers, specialty polymer companies, and distributors. Product availability differs by vinyl acetate content, melt index, molecular weight, medical compliance, manufacturing site, and regional registration.

Potentially relevant supplier categories include:

Supplier category	Typical role
Integrated petrochemical producers	Manufacture base EVA resin at scale
Specialty polymer producers	Offer higher-specification grades
Medical polymer suppliers	Provide documentation and controlled grades
Contract compounders	Modify EVA for device or implant applications
Pharmaceutical distributors	Supply qualified material regionally
Drug-delivery technology companies	Use EVA as part of a proprietary system

Not every commercial EVA grade is suitable for pharmaceutical use. A supplier must normally provide material specifications, manufacturing controls, change-control procedures, impurity information, residual monomer data, extractables and leachables support, and lot-level documentation.

A market participant should distinguish between:

• Commodity EVA resin
• Medical-grade EVA
• Pharmaceutical excipient-grade EVA
• Device-grade compounded EVA
• Finished drug-delivery systems containing EVA

The final category often captures more value than the polymer itself. The intellectual property and margin may sit with the implant architecture, drug loading method, processing conditions, release profile, or finished combination product.

What is the FDA regulatory status of ethylene-vinyl acetate copolymer?

EVA is not an active pharmaceutical ingredient. Its regulatory treatment depends on the finished product, route of administration, use level, and product classification.

The FDA Inactive Ingredient Database is the principal public reference for identifying prior use of excipients in approved drug products. Presence in the database can support regulatory justification, but it does not automatically establish suitability for every route, dosage form, concentration, or product design.[1]

Key regulatory considerations include:

• Prior FDA use by route and dosage form
• Maximum historical concentration
• Polymer composition and grade
• Residual monomers and catalysts
• Extractables and leachables
• Biocompatibility
• Sterilization compatibility
• Particulate and endotoxin controls where relevant
• Stability and container-closure interaction
• Manufacturing-site change control

For implants and combination products, the sponsor may need to provide extensive characterization beyond a conventional oral-excipient package. The polymer’s chemical identity alone is insufficient. Regulators will assess the finished system, including degradation, migration, local tissue exposure, drug-polymer interaction, and release kinetics.

EVA does not have an Orange Book listing because the Orange Book lists approved drug products and associated patents, not standalone excipient materials.[2] It is not subject to Hatch-Waxman exclusivity as an ingredient supplier.

What patents protect ethylene-vinyl acetate pharmaceutical applications?

The base EVA chemistry is mature. Fundamental composition and manufacturing patents are generally old, and commercial exclusivity is more likely to arise from application-specific intellectual property.

Relevant patent categories include:

Formulation patents

These can cover:

• Specific EVA vinyl acetate ranges
• Active ingredient loading
• Pore-forming agents
• Plasticizers
• Polymer blends
• Particle or pellet dimensions
• Release-rate profiles
• Solvent casting methods
• Thermal processing conditions

Device and implant patents

These may claim:

• Reservoir or matrix implant structures
• Membrane thickness
• Drug-core geometry
• Multi-layer devices
• Implant placement and retrieval systems
• Combination products with a specific active ingredient

Method-of-use patents

Method claims can protect:

• Treatment schedules
• Long-acting administration intervals
• Implantation methods
• Release regimens
• Use in specific patient populations

Manufacturing and process patents

Process protection may address:

• Polymer-drug extrusion
• Solvent evaporation
• Hot-melt processing
• Coating and encapsulation
• Sterilization
• Control of porosity and drug dispersion

The patent strength of an EVA-based product depends less on ownership of the polymer and more on whether competitors can reproduce the release profile without practicing protected claims. A broad polymer claim is generally less defensible than a narrow product-by-process or device claim unless the polymer specification is central to performance.

When does EVA pharmaceutical exclusivity expire?

EVA itself does not have a single pharmaceutical exclusivity date. Exclusivity attaches to the finished drug, device, combination product, or patented manufacturing process.

For a drug product, the relevant dates may include:

• New chemical entity exclusivity
• New clinical investigation exclusivity
• Orphan-drug exclusivity
• Pediatric exclusivity
• Listed patent expiration
• Patent-term extension
• Regulatory exclusivity in non-U.S. jurisdictions

For a device or combination product, patent expiration and regulatory market protection may follow different rules. A supplier’s material specification does not create FDA market exclusivity for the finished product.

Are there Paragraph IV challenges involving EVA excipients?

Paragraph IV litigation is generally directed at patents listed for an approved drug product, not at the EVA excipient as a standalone material. A generic sponsor may challenge a drug patent covering an EVA-based formulation, implant, dosage form, or method of use.

The practical litigation questions are:

• Whether the EVA-containing product has Orange Book-listed patents
• Whether the generic product uses the same polymer architecture
• Whether the claims require a specific release profile
• Whether the generic can design around the EVA composition
• Whether infringement can be established from the finished product
• Whether the generic has filed an Abbreviated New Drug Application or another application pathway

No general Paragraph IV risk can be assigned to EVA without identifying the finished drug product and its listed patents.

Is there biosimilar risk for ethylene-vinyl acetate?

Biosimilar risk is not directly applicable to EVA. Biosimilars concern biological products and do not compete with a polymer excipient as a standalone material.

Indirect substitution risk can arise if a biologic or peptide product moves from an EVA-based implant to another delivery platform. Potential alternatives include biodegradable polyesters, injectable depots, osmotic pumps, silicone implants, polyurethane membranes, and hydrogel systems.

The risk is product-specific. A competing delivery system must meet release, stability, biocompatibility, manufacturing, and clinical requirements. Substitution is therefore slower than ordinary excipient replacement but can be commercially material when a new delivery platform reaches approval.

How strong is the patent estate for EVA-based drug delivery?

The EVA material estate is mature and generally weak as a standalone source of exclusivity. The application estate can be stronger.

Patent layer	Typical strength
Base EVA composition	Low to moderate, depending on claim age and scope
Polymer grade specification	Moderate
Drug-polymer formulation	Moderate to strong
Implant architecture	Stronger when difficult to design around
Release profile	Variable and difficult to enforce without testing
Manufacturing process	Moderate
Treatment method	Variable by jurisdiction
Supplier documentation and qualification	Non-patent barrier, often commercially important

The most durable barrier is often regulatory and operational rather than patent-based. A sponsor may avoid changing the polymer because a new grade would require extractables, stability, biocompatibility, process validation, and clinical comparability work.

What generic launch risks exist for EVA-based products?

Generic entry risk depends on product type.

Product type	Generic or competitor entry risk
Conventional oral formulation	Relatively high if formulation claims are narrow
Long-acting implant	Lower because development and clinical requirements are substantial
Drug-eluting device	Moderate, with regulatory classification affecting timing
Simple EVA matrix	Higher design-around potential
Complex multilayer implant	Lower if manufacturing and release claims are strong
Product with scarce clinical data	Lower near term but not permanently protected

Competitors can use a different polymer, alter device geometry, change drug loading, or pursue a different release mechanism. This makes freedom-to-operate analysis essential even when the competitor does not use EVA.

How does EVA compare with competing controlled-release polymers?

Polymer	Main advantage	Main limitation
EVA	Stable, hydrophobic, predictable diffusion, long service life	Non-biodegradable and limited water uptake
PLGA	Biodegradable and widely accepted	Acidic degradation products and variable release
Polyurethane	Flexible and mechanically durable	More complex composition and characterization
Silicone	Biocompatible and established in implants	Processing and drug permeability constraints
Ethylcellulose	Established oral controlled-release polymer	Less suitable for long-term implants
Methacrylate copolymers	Tunable dissolution and release	Route-specific regulatory and formulation limits
Hydrogels	High water content and adaptable release	Mechanical and stability limitations

EVA remains attractive where a durable, non-biodegradable diffusion barrier is acceptable. It is less attractive where biodegradation, rapid formulation changes, or injectable administration is central to the product strategy.

What is the financial trajectory for pharmaceutical EVA?

The expected trajectory is steady rather than explosive.

Base case

Pharmaceutical EVA demand grows slowly through continued use in established implants, drug-eluting devices, and specialty delivery systems. Pricing remains supported by qualification requirements, but total market expansion is limited by low material consumption and a narrow product base.

Upside case

Demand accelerates if long-acting injectables, implantable therapies, and combination products adopt EVA-based delivery systems. New commercial products can produce disproportionate revenue growth for qualified suppliers because each approval creates recurring demand and a long validation cycle.

Downside case

Demand declines if developers favor biodegradable polymers, injectable depots, or alternative device platforms. Solar and packaging markets can also create supply volatility without increasing pharmaceutical demand.

Scenario	Demand outcome	Margin outcome
Base case	Low-single-digit growth	Stable specialty premium
Upside case	Step-up from new approved products	Higher margin and capacity value
Downside case	Flat or declining niche demand	Pressure from substitution and low volume

Exact revenue forecasts should not be derived from the broader EVA market without separating pharmaceutical, medical-device, and industrial grades. The key financial metric is qualified recurring demand, not total global EVA tonnage.

What licensing deals affect EVA pharmaceutical commercialization?

Licensing value usually resides in the finished delivery technology rather than in the EVA resin. Relevant transactions may involve:

• Long-acting drug-delivery platforms
• Implant designs
• Combination-product development
• Polymer-drug manufacturing processes
• Regional commercialization rights
• Supplier qualification and technology transfer

A pharmaceutical company may license a delivery system while sourcing EVA from an approved third party. This separates platform economics from polymer-supplier economics. The technology owner can capture milestone payments and royalties, while the resin supplier receives recurring material revenue.

What geographic coverage matters for EVA excipients?

Regional qualification is important because pharmaceutical manufacturers may require material produced at a specified site under controlled change management.

Key jurisdictions include:

• United States: FDA inactive-ingredient precedent and drug or combination-product review
• European Union: excipient quality and pharmaceutical GMP expectations
• Japan: PMDA review and local quality documentation
• China: National Medical Products Administration requirements and local registration practice
• India: excipient documentation, GMP, and customer-specific qualification
• Global device markets: ISO 10993 biocompatibility and medical-device quality systems

A supplier with multiple manufacturing sites may reduce supply-chain risk, but a site change can trigger requalification. Geographic redundancy therefore has value only when customers approve the alternate site.

Key Takeaways

• Ethylene-vinyl acetate copolymer is a specialty pharmaceutical excipient, not a high-volume pharmaceutical commodity.
• Its main uses are controlled-release implants, drug-eluting devices, transdermal systems, and selected matrix formulations.
• Public data does not reliably isolate pharmaceutical EVA revenue from the much larger industrial EVA market.
• Pricing and financial performance are influenced more by solar, packaging, ethylene, and vinyl acetate markets than by pharmaceutical demand alone.
• EVA’s base polymer patent estate is mature. Commercial protection is more likely to come from formulation, implant, process, and method-of-use patents.
• Orange Book listing, Paragraph IV litigation, Hatch-Waxman exclusivity, and biosimilar competition apply to finished products, not to EVA as a standalone excipient.
• The strongest barriers are qualification, regulatory documentation, manufacturing consistency, and integration into an approved drug-delivery system.
• The market outlook is stable in the base case, with significant upside only if new long-acting or implantable products create recurring demand.

FAQs About Pharmaceutical Ethylene-Vinyl Acetate Copolymer

Is ethylene-vinyl acetate copolymer the same as copovidone?

No. EVA is a copolymer of ethylene and vinyl acetate. Copovidone is a copolymer of vinylpyrrolidone and vinyl acetate and is used mainly as a water-soluble binder and film former.

Is EVA biodegradable in pharmaceutical implants?

No. Conventional EVA is generally non-biodegradable under normal physiological conditions. It remains in the implant unless the device is removed or otherwise designed for retrieval.

Can pharmaceutical companies replace one EVA grade with another?

Not automatically. Differences in vinyl acetate content, molecular weight, additives, residuals, and processing behavior can change drug release and biocompatibility. A grade change generally requires technical and regulatory assessment.

Does EVA create an excipient patent monopoly?

Usually not. EVA chemistry is mature. Exclusivity is more likely to arise from the finished formulation, implant geometry, manufacturing process, or treatment method.

What is the largest commercial risk for an EVA excipient supplier?

The largest risk is customer concentration. A supplier may depend on a small number of approved products, and discontinuation, polymer substitution, manufacturing transfer, or failure of a development program can materially reduce demand.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (2024). Guidance for industry: Use of inactive ingredients in human drugs. U.S. Department of Health and Human Services.
4. International Pharmaceutical Excipients Council. (2022). The IPEC-PQG good manufacturing practices guide for pharmaceutical excipients. IPEC.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
6. European Medicines Agency. (2011). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.
7. U.S. Food and Drug Administration. (2024). Combination products. https://www.fda.gov/combination-products
8. U.S. Food and Drug Administration. (2024). Use of international standard ISO 10993-1, biological evaluation of medical devices. U.S. Department of Health and Human Services.